Conatus Pharmaceuticals Inc. (CNAT) Expected to Post Earnings of -$0.11 Per Share
Wall Street analysts expect that Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will report earnings per share of ($0.11) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Conatus Pharmaceuticals’ earnings. The highest EPS estimate is $0.13 and the lowest is ($0.27). Conatus Pharmaceuticals posted earnings of ($0.30) per share in the same quarter last year, which suggests a positive year over year growth rate of 63.3%. The business is expected to issue its next earnings results on Wednesday, August 2nd.
Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.20. The company had revenue of $7 million for the quarter, compared to analyst estimates of $5.88 million. During the same period last year, the business earned ($0.35) earnings per share.
Several analysts have commented on CNAT shares. ValuEngine raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 24th. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Conatus Pharmaceuticals in a research note on Thursday, June 29th. Finally, Aegis reiterated a “buy” rating and set a $11.00 target price on shares of Conatus Pharmaceuticals in a research report on Friday, May 5th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $13.25.
A number of institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its position in Conatus Pharmaceuticals by 193.5% in the fourth quarter. Renaissance Technologies LLC now owns 183,700 shares of the biotechnology company’s stock valued at $968,000 after buying an additional 121,100 shares during the last quarter. Nationwide Fund Advisors acquired a new position in Conatus Pharmaceuticals during the first quarter valued at about $413,000. Acadian Asset Management LLC acquired a new position in Conatus Pharmaceuticals during the first quarter valued at about $854,000. Bank of New York Mellon Corp boosted its position in Conatus Pharmaceuticals by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company’s stock valued at $464,000 after buying an additional 1,655 shares during the last quarter. Finally, Courage Capital Management LLC boosted its position in Conatus Pharmaceuticals by 25.0% in the first quarter. Courage Capital Management LLC now owns 125,000 shares of the biotechnology company’s stock valued at $721,000 after buying an additional 25,000 shares during the last quarter. Institutional investors own 18.68% of the company’s stock.
Conatus Pharmaceuticals (NASDAQ CNAT) traded down 4.70% during mid-day trading on Thursday, reaching $5.68. The company had a trading volume of 661,637 shares. The company’s market capitalization is $148.64 million. Conatus Pharmaceuticals has a 12 month low of $1.45 and a 12 month high of $9.40. The firm’s 50 day moving average price is $5.74 and its 200-day moving average price is $5.58.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.